

ATTY. DKT.: P-1663-1

UNITED STATES PATENT APPLICATION

OF

RICHARD J. WHITBOURNE,

DANIEL HULLIHEN,

MICHAEL R. VIOLENTE,

FRANK WANG

AND

XIANPING ZHANG

FOR

TARGETED THERAPEUTIC AGENT RELEASE DEVICES

AND METHODS OF MAKING AND USING THE SAME

TARGETED THERAPEUTIC AGENT RELEASE DEVICES
AND METHODS OF MAKING AND USING THE SAME

CROSS-REFERENCE TO RELATED APPLICATION

5 This application claims benefit of U.S. provisional application number 60/196,781 filed
April 13, 2000.

BACKGROUND OF THE INVENTION

Field of the Invention

10 The present invention is concerned with implantable devices having a polymer layer
containing one or more therapeutic agents, i.e., a medicament or medicaments, which devices
are implantable into specific sites, such as tumors or lesions, in a patient's body for sustained
time-release of the one or more medicaments into the specific site, and to methods of making
and using such implantable devices.

15 Related Art
Modern solid tumor cancer therapy typically proceeds along multiple fronts. Surgical
resection, radiotherapy, and chemotherapy are the most common treatment modes, and they are
ordinarily used in various combinations. For instance, resection procedures are usually fol-
lowed by radiotherapy and/or chemotherapy in an attempt to eliminate metastatic cells which
have traveled from the tumors. These treatments are usually traumatic for patients, and often
fail to eliminate the disease.

20 Surgical resection involves the removal of neoplastic tissue along with contiguous tis-
sue, which may contain some tissue that was inadvertently released from the tumor during the
resection procedure. For this reason, resection is usually followed by radiotherapy and/or che-
motherapy. The procedure is traumatic, and leads to physical and esthetic deformation. The
procedure exposes patients to high risks of hospital-acquired nosocomial infections which may
be difficult to treat because drug resistant organisms (Super Bugs) are often involved, and the
patients are often immunocompromised because of disease.

25 30 Radiotherapy involves exposure of neoplastic tissue to radiation designed to kill the
cancerous tissue. The technology has advanced to the point where multiple doses can be si-
multaneously focused on the lesion. This provides higher dosing in the lesion while surround-
ing tissue is exposed to lower doses of radiation. This technology involves complex algorithms,
and dosing errors of an order of magnitude or greater can result. Also, significant collateral
35 damage is inflicted on surrounding tissue.

Brachytherapy uses radioactive "seeds" which must be placed correctly in the tumor or correspondingly inappropriate dosing occurs. The method is very skill-dependent in order to achieve successful outcomes. ~~Brachytherapy has not developed a long record of clinical utility.~~

Chemotherapy involves the administration of cytotoxic agents to patients. These agents 5 are used because they exhibit selective cytotoxicity, and their action against neoplastic tissue can be up to several times that against normal tissue. Chemotherapy is ordinarily administered systemically, usually in aliquots over periods of several days or weeks. This is done in order to reduce unintended adverse effects that result from systemic drug concentrations which are too high to be tolerated by patients. This method is compromised by the fact that maximum systemic drug doses tolerated by patients produce drug concentrations in tumors that are well below the ideal concentrations required to achieve maximum efficacy. Considerable collateral tissue damage results because of the relatively high systemic drug concentrations that are required to achieve significant anti-tumor activity. Patients may become susceptible to infection because drug infusion and disease can compromise their immune systems.

10

15 A major problem with chemotherapy as currently practiced is that much of the drug does not reach the intended target tissue. Systemic drug delivery results in administration of drug to a general compartment (e.g., vasculature) for distribution throughout the body. Some of the drug does reach the intended target site, but most is distributed elsewhere. This "non-targeted" drug is responsible for the adverse effects associated with chemotherapy. Ultimately, of course, 20 the drug is metabolized and excreted from the body.

In contrast, targeted drug delivery provides for the bulk of the drug to be administered directly to the desired site. Some drug still reaches the central compartment for general distribution to non-target tissues, but most of the drug is available for therapeutic effect and only a small fraction results in adverse effects.

25 Various forms of targeted drug delivery have been investigated in an effort to enhance chemotherapy by increasing drug concentrations in the tumors while reducing the systemic drug concentrations. Targeted chemotherapy has been delivered via catheters into vessels feeding tumors or organs containing tumors. In most cases, the medicament or medicaments wash through the tumor too quickly and thus fail to maintain the sustained high, efficacious in-tumor 30 drug concentrations needed for more effective therapy. The results have been somewhat better than systemic administration of chemotherapy, but not as good as desired. Various other techniques employ systemic administration of one or more medicaments that are intended to selec-

tively absorb onto or into tumors, but these techniques result in undesirably high systemic drug levels.

Whitbourne U.S. Patent 5,997,517 discloses bond coats for binding polymeric compositions ("top coats") onto various devices. Several examples show top coats comprising polyvinyl pyrrolidone (PVP) and nitrocellulose.

5 Whitbourne et al U.S. Patent 5,069,899 discloses coatings for medical devices that can contain anti-thrombogenic and anti-microbial compositions. One disclosed coating containing a heparin compound comprised PVP and nitrocellulose (Example 1).

Whitbourne et al U.S. Patent 5,525,348 discloses coating compositions containing anti-thrombogenic and/or antimicrobial agents. The coating contains water-insoluble polymers that may range from hydrophilic to hydrophobic.

10 Li et al U.S. Patent 5,977,163 discloses a targeted drug delivery technique that involves linking paclitaxel or docetaxel to water soluble chelators, polyethylene glycol or a biodegradable polymer such as polyglutamate (PG-TXL). This linkage makes the paclitaxel or docetaxel water soluble, and causes it to selectively absorb into tumors. For example, animal testing showed that more than 300% of the equivalent maximum human dose of paclitaxel can be achieved. However, this method still involves substantial systemic drug concentrations with all of the potential side affects associated with such dosing levels. The use of water-soluble paclitaxel as a coating on implanted medical devices for the inhibition of restenosis is also discussed

15 (col. 5, line 66 - col. 6, line 43; col. 9, lines 23-43).

20 K. Sato et al (Gan To Kagaku Ryoho 1990, Jun 17(6):1105-10) discloses selective intra-arterial infusion of ethylcellulose microcapsules containing an anticancer drug which exerts its therapeutic affects through infarction and sustained drug action (i.e., chemoembolization). This technique relies on the microcapsules embolizing the tumor vasculature and the subsequent diffusion of one or more drugs throughout the tumor(s). The results were better for bladder cancer

25 (54% substantial tumor reduction (STR)), and prostate carcinoma (54% STR), but results were much lower for renal cell carcinoma and hepatoma.

30 Kato et al (Cancer Chemother Pharmacol 1996;37(4):289-96) reviewed the feasibility of intra-arterial infusion of microencapsulated anticancer drugs (chemoembolization). Ethylcellulose microcapsules containing mitomycin C (median total dose 20 mg), cisplatin (60 mg) or peplomycin (40 mg) were given to tumor-feeding arteries by bolus injection. Mitomycin C microcapsules produced a higher response rate. Complete or partial remission of intractable pain and genitourinary gross hemorrhage was found in two-thirds of eligible patients. This modality

is promising, but suffers from the inability to target individual tumors, thus patients experience adverse affects, and drug concentrations in the tumors is less than desired relative to the background-liver-tissue.

5 Kemeny et al (New England Journal of Medicine 1999;341:2039-48) treated patients with six cycles of hepatic arterial infusion with floxuridine and dexamethazone plus intravenous fluorouracil, with or without leucovorin. The study showed improvement in survival, but involved systemic infusions of cytotoxic agents and adverse affects were seen in patients.

Caklakli et al (Acta Oncol 1996;35(4):441-4) evaluated the efficacy of hepatic arterial infusion chemotherapy in the treatment of primary or metastatic liver carcinoma in 37 patients.

10 The infusions were administered through a catheter that was placed in the hepatic artery, either surgically or by percutaneous puncture of the femoral artery. A complete response was observed in four patients. A partial response was observed in six patients and a minor response in another six. In nine patients the disease stabilized, while progression of the disease developed in 12 patients. The response rate (complete, partial, and minor responses) was 43.2% and median survival was 12.0 months. These results are promising. However, there were 17 Grade III toxicities observed, and the therapy was not directed primarily or directly into the patients' tumor or tumors.

15 The delivery of one or more medicaments to specific sites in a patient's body is an issue in fields other than the treatment of tumors. For example, in clinical practice, new strains of organisms have emerged which exhibit significantly more resistance to antibiotic therapy than do previously known strains. Antibiotics are normally administered systemically, either orally or via intravenous injection, so that systemic concentrations which are safe for most patients are achieved. However, these concentrations are below effective levels in the cases of some of the emerging drug-resistant organism strains. It would be advantageous in many cases if one or 20 more medicaments providing anti-infective therapy could be targeted to infected lesions or other specific sites. In this way, it would be possible to achieve higher, more efficacious drug concentrations in the lesions, while systemic drug concentrations would remain at or below levels which are safe for most patients. As with cancer site-targeted therapy, site-targeted antibiotic therapy would be expected to be significantly more efficacious than systemic treatment.

25 It will be seen from the foregoing that need exists for achieving efficacious drug or other medicament concentrations in tumors for extended time periods without concurrent high systemic drug concentrations and for targeted delivery of anti-infective agents such as antibiotics, to sites such as infected lesions.

SUMMARY OF THE INVENTION

The present invention provides a medicated device comprising a scaffold member suitable for implantation at a tumor or other lesion site, a polymeric coating ("med coat") on the scaffold member, and at least one therapeutic agent in the med coat at a loading sufficient to provide therapeutic quantities of the therapeutic agent to the site for an extended period of time.

5 According to one aspect of the invention, the device may comprise an anti-cancer therapeutic agent in the med coat. Optionally, there may be at least 5 micrograms (μg) of at least

one therapeutic agent per square centimeter of the med coat or, optionally, at least 50 μg of at

10 least one therapeutic agent per square centimeter of the med coat or, optionally, at least 100 μg of at least one therapeutic agent per square centimeter of the med coat or, optionally, at least 500 μg of at least one therapeutic agent per square centimeter of the med coat.

15 According to another aspect of this invention, the device may comprise sufficient quantity of a therapeutic agent to deliver a therapeutically effective quantity of a therapeutic agent into tissue in a region of at least one centimeter from the device or, optionally, in a region of at least two centimeters from the device.

20 According to still another aspect of this invention, the med coat may comprise a hybrid polymer coating comprising a hydrophilic polymer component and a hydrophobic polymer component. In one particular embodiment, the polymer coating may comprise an acrylate polymer and PVP/VA copolymer in a weight ratio in the range of from 1.5:1 to 7:1.

25 This invention also provides a medicated device comprising a substrate suitable for implantation in a patient's body a polymeric coating ("med coat") on the scaffold member, and at least one therapeutic agent in the med coat at a loading sufficient to provide therapeutic quantities of the therapeutic agent to the patient's tissue in a region in the body extending at least one centimeter, optionally at least two centimeters, from the device.

30 In one preferred embodiment, the device may comprise a hybrid polymer coating comprising a major proportion of one or more hydrophilic polymer materials and a minor proportion of nitrocellulose, e.g., about 3% by weight of the combined weights of cellulose ester polymer such as nitrocellulose and the hydrophobic materials. In another preferred embodiment, the device may comprise a hybrid polymer coating comprising major portions of hydrophobic and hydrophilic polyurethanes, and cellulose ester such as nitrocellulose, and may contain minor portions of PVP and/or PVP/VA.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic cross section of a device in accordance with one embodiment of the present invention; and

5 Figure 2 is a graph plotting the data of Example 3 and showing on the vertical axis the micrograms of a medicament released from a device of the present invention over a period of time plotted on the horizontal axis.

DETAILED DESCRIPTION OF THE INVENTION

The devices of the present invention can be inserted into lesion/malignant tissue, parenchyma or into the tumor/lesion vasculature where they serve to release therapeutic quantities of a therapeutic agent thereto. The devices comprise substrates that bear one or more layers of medicament-containing polymeric material, or "medicated polymer layers" or "med coats", from which at least one medicament diffuses out into the surrounding medium when hydrated. Body fluid is typically taken up in the medicated polymer layer of the device, and the one or more therapeutic agents, sometimes herein referred to as medicaments or drugs, are released into the surrounding tissue via the fluid. Generally, the present invention provides devices and methods for delivering high, efficacious concentrations of therapeutic agents, i.e., medicaments such as drugs, antibiotics, etc., to specific sites in a patient's body, such as tumors and infected lesions. In one aspect of the present invention there are provided devices to accomplish the aforesaid delivery of therapeutic agents and methods to accomplish the delivery by minimally invasive techniques such as, for example, catheterization or via a trochar.

A particular advantage of this aspect of the invention is that the medicated polymer layer does not need to have high mechanical strength since it relies on the substrate for physical integrity. Prior art implantable products for the delivery of therapeutic agents comprise drug-impregnated polymeric beads or sponges or biodegradable polymers and the like which rely on the physical properties of the impregnated polymer for their physical integrity. Materials commonly used for this purpose in prior art devices include polymethylmethacrylate, ethyl cellulose, poly(L-lactic acid) and/or blends of poly(L-lactic acid) with polycaprolactone or other biodegradable. However, the present invention provides a substrate on which the drug-containing coating layer is carried so the choices of polymers that may be used in the coating formulations of the present invention are far broader than with the other technologies. The present invention provides polymeric matrices that can match the needs for each product mission in terms of drug release rates, drug stabilization, drug compatibility, resistance to degradation caused during

sterilization, and *in vivo* exposure. Conversely, the choice of materials used for the carrier substrate is not restricted to those capable of releasing therapeutic agents.

In another aspect of the present invention, the devices are of such size and shape as to allow them to be delivered to a target site, such as a tumor or lesion, for example, by a trochar or catheter placement or otherwise. Such devices may be shaped as mandrels, beads, cylinders, egg-shaped articles, spheres, coiled or straight articles such as threads or wires, or other configurations. Such articles may have dimensions ranging from diameters of less than 1 mm to greater than 10 mm, and lengths of up to 40 centimeters ("cm") or more. Typically, the largest dimension (length, width or height) for an implantable device is not more than 10 mm, e.g., in

10 the range of from 2 to 5 mm. Such shapes and dimensions are merely illustrative of some embodiments of the invention, and are not intended to limit the dimensions or shapes of the articles that are embraced by the invention. In certain embodiments, the substrate on which one or more polymer coatings are applied is configured to serve as a scaffold for the coating materials. A "scaffold" is a substrate configured to have adjacent edges or surfaces in close proximity to

15 each other so that the coating material, when applied, will not only coat the surfaces but will bridge from one surface to the other. For example, a scaffold may be provided by a wire configured into a coil having open windings. When the polymer coating is applied to the scaffold, it not only covers the surface of the wire but also bridges from one winding to the next so that the finished device may have the shape of a cylinder with the coiled wire scaffold embedded

20 therein. Other scaffolds include perforated wafers, wire meshes, and the like. Thus, a scaffold differs from other substrates such as straight wires, pellets, tubing, stents and other devices to which lubricious coatings have been applied in the prior art. In all such embodiments, the scaffold provides the structural support for the device so that the coating material can be chosen for its rate of release of the drugs incorporated therein without regard to the structural strength of

25 the coating itself.

Depending on which substrate material is selected, the coating containing the medicated polymer layer (the "med coat") may comprise one or more layers. The medicated polymer layers of this invention may be applied directly on substrates such as polyvinylchloride (PVC) and many polyurethanes. Other substrates exhibit better adhesion when one or more layers of

30 bonding material are used in order to prime the surface so that the medicated layer(s) will be properly anchored to the substrate. Metals such as stainless steel, and some plastics such as polyamides or polyolefins can require such priming layers to achieve the adherence needed on medical devices intended for *in vivo* placement. Such bonding layers are described in U.S. Pat-

ent 5,997,517 and its divisional applications and continuation-in-part applications, and foreign counterparts thereof, the respective disclosures of which are incorporated herein by reference.

Briefly restated, U.S. Patent 5,997,517 teaches that thin-bond-or-tie-coat-layers may be applied to difficult-to-bond-to substrates in order that other layers which cannot normally be bonded to such substrates may be satisfactorily bonded. The polymers used for this purpose are sufficiently resistant to degradation by solvents in succeeding layers that the coating does not lose adhesiveness when soaked in water and is impervious to water diffusion from the surface.

Classes of polymers which may be employed include acrylic polymers and copolymers based on monomers such as methylmethacrylate, butylmethacrylate, isobutylmethacrylate, ethyl-

10 methacrylate, methylacrylate, acrylic acid, styrene methacrylate, styrene acrylate, and others; vinyl polymers and copolymers such as polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymers, ethylene acrylic acid copolymers, epoxy polymers, and others. Exemplary commercial products that may be used in the invention include acrylics such as ARYLOID® (Rohm & Haas) AT-63, AT-51, AT-81, WR-97; Polyvinylpyrrolidone polyvinyl acetate copolymers such as PVP/VA (GAF) E-335, E-635; ethylene acrylic acid copolymers such as PRIMACOR™ (DOW) 5989, 5990; melamine resins such as CYMEL (CYTEC Industries) 303, 370, 380; epoxies such as EPON (Shell) 1001. Other appropriate polymers having the requisite characteristics will be apparent to persons of ordinary skill in the art.

20 The bonding polymers preferably, but not necessarily, contain reactive groups or points of reactivity such as hydroxyls, mono-, di- and tertiary amines, acids such as carboxyl, amides, or other groups which represent points of chemical reactivity. The bonding polymers and points of chemical reactivity are able to form attractive forces such as hydrogen bonding toward the medical device surface, and also toward the coating layers to be applied over them. Such bonds are very strong, and prevent penetration of the top coat layer and water without requiring 25 covalent or other ionic links between the device surfaces and the thin polymer tie coatings.

Polymers with reactive groups are preferred to help bond with substrates like metals. However, bonding polymers lacking such groups such as acrylic or styrene polymers may also be used.

30 The reactive groups can also react to form a cross-linked matrix or help to form a cross-linked matrix. If desired, cross-linkers such as urea resins, melamines, isocyanates, phenolics, and others may be incorporated to cross-link the polymers of the invention with themselves, by reacting with the points of chemical reactivity on the polymer chains. Alternatively, cross-linkers may react with themselves to form a cross-linked matrix in which the tie coat polymers

are enmeshed, resulting in a solvent-resistant layer. Cross-linking within the thin polymeric tie coats (either between the principal polymers or around them) is useful in promoting effective adhesion by ensuring that the solvents used in succeeding coating layers do not attack and degrade the tie coat polymer layer excessively and by resisting water penetration. When the tie coat layers are subjected to excessive solvent attack the tie coat polymer layer may be diluted by the succeeding coating layer thereby degrading the adhesive bond between the tie coat layer and the medical device surface. Excessive water penetration can also degrade adhesion.

5 Bond coatings according to the invention may be prepared with polymers that lack points of reactivity, such as acrylic or styrene polymers or copolymers. Likewise, coatings may 10 be made without cross-linking. However, with such coatings a greater tie-coat thickness may be required or desirable than with layers made of polymers with points of reactivity and layers with cross-linking, in order to achieve a high degree of adhesion of succeeding layers according to the invention.

15 The bond coat or layer may be thin, on the order of 0.0002 inch to 0.0005 inch (5 to 12 micrometers or "microns"), although it may be as thick as is desirable. Preferably, it is in the range of about 2 to about 100 microns, more preferably less than about 80 microns, or 60 microns, and particularly preferred embodiments are less than about 15 microns thick. Bond coats of about 2 to about 10 microns are generally quite adequate. If the coating is thicker, it may cause other problems in certain applications where thinness is important.

20 Examples of substrates and bond coat formulations that are effective with them are listed below. Many other combinations will be apparent to a person of ordinary skill in the art following the teachings of the invention.

stainless steel substrate:

25 epoxy resin; vinylpyrrolidone-vinyl acetate copolymer; styrene
acrylic aqueous dispersion; ethylene acrylic acid copolymer
plus melamine resin; ethylene acrylic acid copolymer
plus melamine resin plus hydroxyl function acrylic
polymer plus isocyanate polymer; carboxyl function
acrylic polymer plus epoxy resin; acrylic dispersion polymer

30 polyethylene substrate:

ethylene acrylic acid copolymer plus melamine resin plus
hydroxyl function acrylic polymer plus isocyanate polymer
ethylene acrylic acid copolymer plus melamine resin plus

hydroxyl function acrylic polymer plus isocyanate polymer
plus oxygen plasma

polyester substrate:

5 ethylene acrylic acid copolymer plus melamine resin plus
hydroxyl function acrylic polymer plus isocyanate polymer

polyamide substrate:

oxygen plasma plus polyvinylbutynal

The bond coatings may be coherent in that they form a continuous surface layer. When
10 coated with a top coat such as a medicated polymer layer, the resulting coatings are resistant to
removal on prolonged soaking in aqueous fluids, and are adherent to a wide variety of sub-
strates.

The bond coatings may be applied by various techniques such as dip, spray, brush, wipe,
or other methods known to those skilled in the art. The coating solutions have low viscosities,
15 typically less than 100 CPS, and have good spreading properties. The coatings are baked at
elevated temperatures, typically 50°C to 100°C, to drive off the organic solvents.

Gas plasma treatment may be done according to conventional methods. A vacuum is
drawn, a gas such as oxygen or ammonia is allowed in, it is excited with Rf radiation, and the
surface is allowed to stay in contact with the resulting plasma for a sufficient time, such as 20
20 minutes, to put functional groups on the surface. Oxygen produces hydroxyl surface groups,
and ammonia produces amine groups covalently bound to the polymer surface. Over time the
groups tend to fold into the surface and become less reactive, so plasma-treated surfaces are best
used fresh.

The bond coating systems described herein produce coatings that remain bonded in
25 aqueous fluids on surfaces such as polyethylene, polypropylene, polyamide, polyester, silicone
and metals such as stainless steel, platinum, gold, nickel, titanium, nickel-titanium alloys,
chrome and other surfaces that are generally considered as presenting adherence problems. It
may be necessary to treat some surfaces with gas plasma or other ionizing treatment to promote
adhesion to the substrates.

30 Optionally, one or more tie coat layers may be applied on the bond coat beneath the med
coat. A tie coat layer may comprise any suitable material for joining the med coat to the bond
coat. Polyurethanes and other materials may be used for this purpose.

Another aspect of the present invention is that a med coat may comprise a hybrid poly-
meric material comprising hydrophilic and hydrophobic polymers, which are incorporated such

that the appropriate degree of hydrophilic/hydrophobic balance is obtained to meet the desired drug release requirements. Polymer matrices that are less hydrophilic will ordinarily have slower moisture diffusion and therefore produce slower drug diffusion rates. More hydrophilic polymer matrices will usually have faster moisture diffusion rates and therefore produce faster drug diffusion rates. Cross-linked polymer matrices will usually have slower diffusion rates than similar polymer matrices that are not cross-linked.

A variety of hydrophilic and hydrophobic polymers for use in such a hybrid are known in the art. For example, suitable hydrophilic polymers include polyvinylpyrrolidone (PVP), PVP/vinyl acetate copolymer (PVP/VA), polyethylene glycol, polyethylene oxide, polyvinyl alcohol, a polyether, polysaccharide, hydrophilic polyurethane, polyhydroxyacrylate, polymethacrylate, dextran, xanthan, hydroxypropyl cellulose, methyl cellulose; or a homopolymer or copolymer of a vinyl compound having polar pendant groups, N-vinyl lactam such as N-vinylpyrrolidone, N-vinyl butyrolactam, N-vinyl caprolactam, an acrylate or methacrylate having hydrophilic esterifying groups, hydroxyacrylate, and acrylic acid, polyacrylamide/ethylene glycol copolymer and polyacrylamide/polyethylene oxide copolymer; or a combination thereof.

Suitable hydrophobic polymers include a cellulose ester or ether, ethyl cellulose, hydroxyethyl cellulose, cellulose nitrate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, polyurethane, polyacrylates, a natural or synthetic elastomer, rubber that is soluble in organic solvents, acetal, nylon, polyester, styrene polybutadiene, acrylic resin, polyvinylidene chloride, polycarbonate, homo- and copolymers of vinyl compounds, polyvinylchloride, polyvinylchloride acetate, acrylate/carboxyl copolymer and combinations thereof. In a specific embodiment, a hybrid coating may comprise a combination of an acrylate polymer and a PVP/VA copolymer in a weight ratio in the range of from 1.5:1 to 7:1.

The hybrid polymer layer of the devices of the present invention can be formulated to release large amounts of drug at first, followed by a sustained drug release over extended time periods to achieve more efficacious performance. We have now found that surprisingly high drug loads that were not contemplated in prior patents U.S. Patents 5, 069,899 and 5,525,348 can be incorporated in the hybrid polymer layers. These and other prior art patents show coatings impregnated with anti-thrombogenic, anti-microbial and other agents only to the extent to prevent inflammation infection, etc., resulting from the placement of the device in the body ("prophylactic use") and not in amounts that permit the use of the device as a means of delivery of amounts of drugs effective for the therapeutic treatment of such pathologic conditions prior to the introduction of the device ("therapeutic use"). Such elevated loadings can be one, two or

even three orders of magnitude greater than is employed in prior art coatings. For example, a device containing prophylactic quantities of a medically active agent, anti-thrombogenic, antibiotic, etc., may contain several milligrams of the agent per square centimeter of the coating surface, whereas a device according to this invention may contain hundreds or thousands of 5 milligrams per square centimeter. The elevated drug loads carried in the hybrid polymer layers therefore make it possible to insert devices that are capable of sustaining greatly elevated medicament(s) burdens, such as anti-cancer drugs in tumors, over extended time periods. The drug release rates can be controlled over wide ranges by several factors, including drug solubility in water and in the patient medium, diffusion rates of body fluids into the hybrid polymer layer, 10 ratio of the drug or drugs to the polymer matrix in the polymer layer, chemical/physical interactions between the drug or drugs and polymer matrix, the degree of cross-linking in the hybrid polymer layer, the layer thickness of the hybrid polymer base, and the relative proportions of hydrophilic and hydrophobic polymer materials in the coating.

For example, a hybrid polymer coating comprising roughly equal amounts of one or 15 more hydrophilic polymers or copolymers and one or more hydrophobic polymers or copolymers will admit water into the coating at a much greater rate than a coating comprising only a minor proportion of hydrophilic polymers or copolymers. This invention demonstrates that by reducing the proportion of hydrophilic polymers, the coating can be loaded with large amounts of therapeutic agents and that elution will occur over extended periods of time, e.g., at least two weeks, or at least a month or, optionally, several months. Coatings of devices in accordance 20 with this invention can therefore be designed to provide therapeutic amounts of therapeutic agents to tissue in areas of up to one, two or three centimeters from the implant site, whereas prior art devices were typically capable of delivering effective amounts of active agents to areas within only one or two millimeters from the implant site. As demonstrated in the example below, by employing a coating comprising principally hydrophobic polymer materials with a minor proportion of hydrophilic polymer materials, the rate at which a therapeutic agent is delivered 25 to surrounding tissue can be extended and regulated.

Regardless of the relative proportions of hydrophilic and hydrophobic coatings in the coating, higher ratios of drug to polymer binder lead to more rapid drug release rates, while 30 higher ratios of polymer binder to drug(s) result in slower release rates. Drugs which are more soluble in the patient's tissue/fluid medium will release more rapidly from the coating, and less soluble drugs will release more slowly from the coating.

The med coats of this invention are thin (typically less than 200 micrometers (μm) in thickness), and can be smooth or porous. The coats are made to be flexible or rigid, depending on the product mission, but as discussed above, the use of a scaffold or other substrate will alleviate the need to produce a mechanically strong or rigid coating. The hybrid polymer layers 5 may be prepared as generally described in one or more of U.S. Patents 5,001,009; 5,069,899; 5,331,027; 5,525,348; 5,800,412; 5,997,517; 6,110,483; PCT/US97/18477; and their U.S. and foreign counterparts. The disclosures of each of the foregoing patents and applications are hereby incorporated herein by reference.

One advantage of this invention is the fact that the layers can accommodate a wide variety of drugs, and the drugs can be incorporated in the same or contiguous layers. The devices 10 and methods of the present invention provide sustained, high efficacious medicament concentrations in selected sites such as tumors or lesions for time periods of from a few days to several weeks. The present invention also provides high medicament concentrations in specific sites, e.g., tumors or lesions, while systemic medicament concentrations are kept to very low, safer 15 levels, much lower than those which are encountered in systemic drug therapy.

One embodiment of a targeted delivery device in accordance with the present invention is illustrated in Figure 1. The device 10 comprises a carrier substrate 12 and a coating 14 comprising a single medicated polymer layer of polymeric material. Dispersed within the medicated polymer layer is a dose of therapeutic agent schematically represented by dots 16. The polymeric material in coating 14 is chosen for good adherence to carrier substrate 12, which may comprise, e.g., polyvinylchloride (PVC) so that no binder layer is needed between the 20 medicated polymer layer and the substrate. Coating 14 is porous or water-permeable and, upon insertion into tissue, water diffuses into coating 14 as indicated by arrow 18. Therapeutic agent contained within coating 14 is carried by the water out from coating 14 as indicated by arrows 25 20 and is thus delivered into the adjacent tissue. Therapeutic agent near the exposed surface of coating 14 diffuses out from coating 14 more quickly than therapeutic agent disposed closer to substrate 12. As indicated above, substrate 12 is preferably chosen for its structural properties so that the polymeric material in the medicament-containing layer of coating 14 can be chosen for its diffusion properties rather than its structural properties. Optionally, the medicament-containing layer of coating 14 comprises a hybrid polymer layer of hydrophobic and hydrophilic polymeric materials, as described above. In alternative embodiments, coating 14 may 30 comprise a plurality of layers, optionally a plurality of medicament-containing layers and/or

non-medicament-containing layers such as a bond coat layer to enhance adhesion between the other layer(s) and substrate 12.

Devices of the present invention can be used to deliver many kinds of therapeutic agents for therapeutic processes, e.g., anti-cancer agents such as paclitaxel, taxotere, fluorouracil, dox-
5 arubicin, methotrexates, cisplatin, mitomycin, peplomycin, merbarone, alone and in combinations; anti-infective agents including antibiotics such as rifamycin, minocycline, penicillins, cephalosporins, fluoroquinolones, Tetracyclines, Chloramphenicol, Polymixin B sulfate, Bacitracin zinc, aminoglycosides, cilindamycin, and lincomycin, and/or anti-microbial agents such as benzalkonium chloride, Bronopol, thymol, silver compounds, polyhexamethylenebeguanide
10 hydrochloride, benzethonium chloride, stearalkonium chloride, 1,2-benzisothiazolin-3-one and, tricosan vantacil, alone and in combinations; anti-thrombogenic agents such as heparin sodium, heparin complexed with quaternary ammonium compounds such as benzalkonium chloride, ste-
aralkonium chloride, or tridodecylmethylammonium chloride, hirudin, sugars, and aspirin, alone and in combinations; anti-viral agents or vector, DNA, enzymes, etc., alone or in combinations.
15 Clotting agents such as thrombin, fibrin, and/or antiangiogenic agents such as Can-
statin, paclitaxel, 2C3 anti-vascular endothelial growth factor (from the University of Texas) and peptides are disclosed in U.S. Patent 5,994,309 and may also be incorporated. Any suitable therapeutic agent or combinations of two or more thereof ("drug cocktails") can be delivered by the devices and methods of the present invention.

20 The following examples are illustrative, and are not intended to limit the scope of the invention.

Example 1 (Prior art layer on polyurethane)

A quantity of 2 milliliters ("ml") sodium methotrexate (25 mg/ml) was placed in a test
25 tube and 4 ml ethanol was added. The methotrexate precipitated out of solution. Tridodecyl-
methylammonium chloride (TDMAC) was added in an amount sufficient to react with all the
methotrexate present, and the test tube was swirled to mix the agents. The methotrexate quickly
went into solution as the TDMA salt. This mixture was shaken with an equal volume of toluene
30 to separate the water and sodium chloride from the methotrexate-TDMA salt. The toluene layer
separated to the top and had characteristic yellow color of methotrexate salts. The aqueous
layer was clear and had no color. The toluene layer was diluted with an equal volume of 2%
cellulose acetate butyrate in butyrolactone. This was coated on a polyurethane catheter surface
and produced a clear layer. (This is Example 20, from U.S. Patent 5,525,348, the disclosure of
which is incorporated herein by reference.)

Example 2 (Prior art)

The following solution was coated on glass and dried for 2 minutes at 80°C.

Merbarone	0.10 gm
Dimethyl sulfoxide	1.98 gm
Cellulose acetate butyrate	0.12 gm
Ethanol	2.0 g,

This solution was clear, and dried to a clear layer when coated on glass.

5 Examples 1 and 2 demonstrate that it is possible to formulate homogeneous solutions containing polymer and pharmaceutical agents which can be cast on surfaces and will dry to form clear, homogeneous, polymeric alloy. (This is Example 22 from U.S. Patent 5,525,348, the disclosure of which is incorporated herein by reference.)

Example 3

The following solutions were prepared.

E3-PC

Acrylate/carboxyl polymer, 55.5% solution(1)	8.33 gm
Tetrahydrofuran (THF)	39.58 gm
Cyclohexanone	41.60 gm
PVP/VA Polymer Solution (2)	2.73 gm
Ethanol	1.37 gm
Epoxy polymer Solution (3)	1.20 gm

E3 - Med Coat

Epoxy Polymer Solution (3)	2.56 gm
PVP/VA Polymer Solution (2)	2.79 gm
Acrylate/carboxyl polymer, 55.5% Solution (1)	8.50 gm
Cyclohexanone	42.70 gm
THF	36.70 gm
Ethanol	5.56 gm
Paclitaxel	1.00 gm

(1) This copolymer solution is 55.5 % (w/w) solids in aromatic 150/butyl cellosolve, 87.5/12.5.

15 (2) This copolymer solution is 50.0 % (w/w) solids in ethanol.

(3) This epoxy polymer is 75 % (w/w) solids in xylene.

Solution E3-PC was coated on stainless steel coronary stents, and dried for 60 minutes at 120°C. This layer was applied twice. Solution E3 - Med Coat was coated over the precoat layers, and dried for 60 minutes at 120°C. Drug loading on the stents in the range of 50-60 µg was achieved by applying the Med Coat three times. The stent samples with three layers of E3

5 - Med Coat were subjected to elution in room temperature phosphate buffered saline for times up to 336 hours, and produced the results set forth in TABLE I.

TABLE I

Test No: A99-155

10

Test Items: Paclitaxel Extracts

Sample Identification and Elution Time	Analysis #1 Paclitaxel Conc. (µg/ml)	Analysis #2 Paclitaxel Conc. (µg/ml)	Average Paclitaxel in Eluent (µg/ml)	Extract Volume (ml)
TDH042799-1, 2 hr.	0.6	0.7	0.65	1.5
TDH042799-1, 4 hr.	0.5	0.5	0.50	1.5
TDH042799-1, 6 hr.	0.4	0.4	0.40	1.5
TDH042799-1, 8 hr.	0.3	0.4	0.35	1.5
TDH042799-1, 24 hr.	0.3	0.3	0.30	1.5
TDH042799-1, 48 hr.	0.3	0.3	0.30	1.5
TDH042799-1, 168 hr.	0.4	0.4	0.40	1.5
TDH042799-1, 216 hr.	0.3	0.3	0.30	1.5
TDH042799-1, 336 hr.	0.3	0.3	0.30	1.5

TABLE II

Sample Identification	µg Paclitaxel Released	% of Total Paclitaxel released over 336 hours	Elution Time Cumulative Hrs.	Paclitaxel Release Cumulative µg
TDH042799-1, 2 hr.	0.98	18.6	2	0.98
TDH042799-1, 4 hr.	0.75	14.3	4	1.73
TDH042799-1, 6 hr.	0.60	11.4	6	2.33
TDH042799-1, 8 hr.	0.53	10.0	8	2.85
TDH042799-1, 24 hr.	0.45	8.6	24	3.30
TDH042799-1, 48 hr.	0.45	8.6	48	3.75
TDH042799-1, 168 hr.	0.60	11.4	168	4.35
TDH042799-1, 216 hr.	0.45	8.6	216	4.80
TDH042799-1, 336 hr.	0.45	8.6	336	5.25

The data of TABLE I and TABLE II show that approximately 10 % of the paclitaxel eluted out over a period of 14 days. The data are plotted on the graph of Figure 2 and show the cumulative quantity of paclitaxel eluted, in micrograms, over a period of 336 hours (14 days).

5

10

Example 4

Silicone rubber tubing was dipped briefly in a 4 % (w/w) solution of benzoylperoxide, and dried under ambient room conditions. After drying, the tubing was placed in a reactor that contained the following aqueous monomer solution.

Acrylamide derivatives	32.8 gm
Diacrylate cross-linker monomer	2.0
Polyvinylpyrrolidone	0.16
Sodium Chloride	120.0
Water to	800.0

15

The system was degassed at 1.0 mm Hg for ten minutes. The reactor was then placed in a water bath at 87°C for about one hour, and the reaction system was stirred at low speed on a magnetic stirrer. After the graft reaction, the tubing was rinsed with water and dried. The surface layer displayed excellent adhesion to the silicone tubing when tested with Scotch® tape.

The grafted samples were soaked for five minutes in solutions containing biologically active agents, as shown in the Table below, and rinsed with deionized water and dried. The

samples were then tested for elution of active agents by zone of inhibition against *staphylococcus A* organism. The following table lists the results. It is clear that each of the active agents diffused out of the graft layer over distances of from 6 to 38 mm.

<u>Physiological Agent</u>	<u>Zone size (mm) against S. Aureus (4 samples)</u>
4.8 % Rifamycin	32, 33, 33, 35
1.9% Gentamicin laurylsulfate	12, 12, 12, 13
2.0% VANTOCIL®IB	9, 9, 10, 10
4.8% Benzalkonium chloride	16, 16, 16, 16
2.0% BRONOPOL-BOOTS® BP	38, 38, 38, 38
2.1% silver nitrate	11, 12, 12, 12
1.0% methotrexate	10, 11, 11, 11
1.1% paclitaxel	6, 6, 6, 7

Example 5

Stainless steel coil guide wires of 0.038 inches in diameter (0.965 mm) were sealed in a hybrid polymer sleeve made of polyurethane and cellulose nitrate (PU/CN) polymers. The hybrid polymer is proprietary to STS Biopolymers, Inc. of Henrietta, New York. Next, a hybrid polymer layer containing polyvinylpyrrolidone and cellulose nitrate with 33% paclitaxel was cast over the sleeves. The samples were evaluated for drug loading by high pressure liquid chromatography (HPLC) analysis under the following conditions.

Column - 10 x 0.4 cm Hypersil C18, 5 micron

Column temperature - ambient

Mobile phase - 1.1 acetonitrile:water

Flow rate - 1.0 ml/min

Detector - UV at 228 nm

Injection volume - 20 microliters

Retention time - about 6 minutes

20

Results show the following drug loading expressed as micrograms ("μg") of drug per linear centimeter of the wire ("μg/linear cm").

Sample 1 423 μg/ linear cm.

Sample 2 560 μg/ linear cm.

25

Average 492 μg/ linear cm.

TABLE III

An elution analysis in calf serum was performed with the following results.

<u>Elution Time</u>	<u>Paclitaxel Remaining</u>
5	0 days 408.1 micrograms/centimeter
	1 day 298.0 micrograms/centimeter
	3 days 132.4 micrograms/centimeter
	5 days 68.3 micrograms/centimeter
	7 days 29.2 micrograms/ centimeter

10

Example 6

Three coating formulations designated A, B and C were prepared as follows.

TABLE IV

(All percents are expressed as w / w %.)

<u>Component</u>	<u>A</u>	<u>B</u>	<u>C</u>
Benzalkonium heparinate (HBAK)	2.00%	2.00%	2.00%
Hydrophobic polyurethane	4.30%	0.00%	0.00%
Ultra Hydrophilic polyurethane	0.00%	4.30%	0.00%
Hydrophobic polyurethane	0.00%	0.00%	3.65%
Nitrocellulose, RS, 5-6 sec.	4.30%	4.30%	4.30%
Polyvinylpyrrolidone (PVP)	0.00%	0.00%	0.65%
N-methylpyrrolidone	16.40%	16.40%	16.40%
Tetrahydrofuran	25.90%	25.90%	25.90%
Ethanol	47.10%	47.10%	47.10%

15

Each of the coatings was applied to a tube substrate to approximate the loading on a stent and the resulting devices were tested for drug release by placing them in serum and incubating them at 37°C with continuous gentle swirling. The serum was exchanged with fresh serum every Monday, Wednesday and Friday. The results, indicating the heparin content of the serum measured on the indicated day are set forth in TABLE V.

20

TABLE V

(Data indicate estimated USP heparin units released into the serum per cm of the substrate.)

<u>Day</u>	<u>Device Coating</u>		
	<u>A</u>	<u>B</u>	<u>C</u>
1	0.275	1.58	0.68
2	0.275	1.75	0.65
4	0.02	1.8	0.4
7	0.02	0.9	0.55
11	0.02	0.7	0.38
14	0.02	0.8	0.35
18	0.02	0.5	0.13
21	0.02	0.5	0.1
25	0.01	0.5	0.08

These data show that sample C provided a longer and more uniform release of the drug than did either of the other two samples. Sample C differed from Samples A and B in that Sample C contained principally hydrophobic polymer materials with a small amount of a hydrophilic material (PVP). In contrast, Sample A contained only hydrophobic polymer materials and Sample B contained approximately equal quantities of hydrophobic and hydrophilic materials. The data therefore show that by employing a minor proportion of hydrophilic material in a hybrid polymer coating, the release of a therapeutic agent can be well regulated.

Example 7

Three coating materials designated E, F and G were prepared as follows.

15

TABLE VI

<u>Component</u>	<u>E</u>	<u>F</u>	<u>G</u>
Hydrophilic polyurethane	6.07%	0.00%	1.50%
Ultra hydrophilic polyurethane	0.00%	6.07%	0.00%
Hydrophobic polyurethane	0.00%	0.00%	1.50%
Nitrocellulose RS, 5-6 sec.	2.43%	2.43%	1.20%
Tetrahydrofuran	54.64%	54.64%	51.30%
Ethanol	21.85%	21.85%	20.60%
Dimethyl-sulfoxide	15.01%	15.01%	23.90%

Two portions of coating material E and two portions of coating material G, designated E1,E2, G1 and G2, respectively, were prepared. E1 and G1 each contained 6% paclitaxel while E2 and G2 each contained 6% paclitaxel and 2% HBAK. The coatings were then coated onto wire substrates to simulate stents and the resulting devices were tested as described in Example 6. The 5 results at the start, and on days 1, 3 and 7 are set forth in the following TABLE VII.

TABLE VII

Device Coating	Days			
	0	1	3	7
E1	140	71	45	18
E2	122	49	32	---
G1	119	48	30	---
G2	102	45	22	---

(Data indicate μg paclitaxel released from the simulated stent at the indicated day.)

10 The data of TABLE VII show that the combination of an anti-thrombogenic agent with an anti-cancer agent in the polymer coating does not substantially affect the elution rate of the anti-cancer agent.

15 A 6% quantity of paclitaxel was added to coating material F and several substrates were then coated with material F. The resulting devices were tested as described above and measurements were made by stripping the substrates at the start, and on days 1, 3, 7, 10, 14, 21 and 28 to determine the paclitaxel loading on the substrate. The results are set forth in TABLE VIII as follows (each datum being the average measurement from two samples taken on the indicated day).

TABLE VIII

Day	0	1	3	7	10	14	21	28
μg paclitaxel	770	840	460	230	490	18	17	20

(Data indicate the amount of paclitaxel remaining in the coating on the indicated day.)

25 Allowing for minor variations in the original paclitaxel content among the samples, the data for TABLE VIII show that therapeutic quantities of paclitaxel are available in the coating even after 28 days of elution.

While the invention has been described with reference to specific embodiments thereof, it will be apparent upon a reading and understanding of the foregoing that numerous alterations to the described embodiments will occur to those of ordinary skill in the art and it is intended to include such alterations within the scope of the appended claims.

